Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: Gene fusions are established oncogenic drivers and emerging therapeutic targets in advanced colorectal cancer. This study aimed to detail the frequencies and clinicopathological features of gene fusions in colorectal cancer using a circulating tumor DNA assay. METHODS: Circulating tumor DNA samples in patients with advanced colorectal cancer were analyzed at 4,581 unique time points using a validated plasma-based multigene assay that includes assessment of fusions in FGFR2, FGFR3, RET, ALK, NTRK1, and ROS1. Associations between fusions and clinicopathological features were measured using Fisher’s exact test. Relative frequencies of genomic alterations were compared between fusion-present and fusion-absent cases using an unpaired t test. RESULTS: Forty-four unique fusions were identified in 40 (1.1%) of the 3,808 patients with circulating tumor DNA detected: RET (n = 6; 36% of all fusions detected), FGFR3 (n = 2; 27%), ALK (n = 10, 23%), NTRK1 (n = 3; 7%), ROS1 (n = 2; 5%), and FGFR2 (n = 1; 2%). Relative to nonfusion variants detected, fusions were more likely to be subclonal (odds ratio, 8.2; 95% CI, 2.94 to 23.00; P < .001). Mutations associated with a previously reported anti–epidermal growth factor receptor (anti-EGFR) therapy resistance signature (subclonal RAS and EGFR mutations) were found with fusions in FGFR3 (10 of 12 patients), RET (nine of 16 patients), and ALK (seven of 10 patients). For the 27 patients with available clinical histories, 21 (78%) had EGFR monoclonal antibody treatment before fusion detection. CONCLUSION: Diverse and potentially actionable fusions can be detected using a circulating tumor DNA assay in patients with advanced colorectal cancer. Distribution of coexisting subclonal mutations in EGFR, KRAS, and NRAS in a subset of the patients with fusion-present colorectal cancer suggests that these fusions may arise as a novel mechanism of resistance to anti-EGFR therapies in patients with metastatic colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · cited 1×
“METHODS Patient Population A cohort of 4,289 consecutive patients with stage III or IV CRC underwent molecular profiling at 4,581 unique time points between February 2015 and December 2017 using a validated plasma-based 68-, 70-, or 73-gene ctDNA NGS assay (Guardant360, Guardant Health, Redwood City, CA), as previousl…”
MethodAmplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · cited 8×
“© 2019 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License INTRODUCTION Fusions resulting in activation of proto-oncogenes lead to pathologic proliferation in a variety of malignancies and can serve as potential therapeutic targets.1,2 Although selective kinase inhibito…”
BackgroundInfluentialOdegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., Fairclough, S. R., Zill, O. A., Sikora, M., Mokhtari, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3831 · Cited by 435
Self-citationZill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391 · cited 4×
“When measured by ctDNA, early truncal mutations tend to occur at higher variant allele fractions (VAFs) compared with mutations acquired later in disease progression.(13) ctDNA may thereby uncover the genomic evolution of mechanisms of treatment resistance, because subclonal mutations not initially detected in primary…”
BackgroundMethodInfluentialSelf-citationRankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
Self-citation
Cited by
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Resistance to anti-EGFR therapy also occurs in mCRC expressing ALK fusions (0.2% of cases) or neurotrophic tyrosine receptor kinase ( NTRK) fusions (0.7%), and these may be detected through sequencing circulating tumor DNA (ctDNA) [62].”
BackgroundInfluentialTopham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Lee, Y. S., Li, W., Banks, K. C., Quinn, K., Renouf, D. J., Jonker, D. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00364 · Cited by 70
Self-citationAnti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
“Intratumoral heterogeneity is a central feature of colorectal cancer and decisively influences this acquired resistance [108].”
Gmeiner, W. H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242224 · Cited by 18
Metadata
- Authors
- Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., Sherrill, G., Fanta, P., Grothey, A., Hendifar, A., Henry, D., Mahadevan, D., Nezami, M. A., Tan, B., Wainberg, Z. A., Lanman, R., Kopetz, S., & Morris, V.
- Venue
- JCO Precision Oncology
- Published
- 2019-12
- Volume
- 3
- Issue
- 3
- Pages
- 1-15
- ISSN
- 2473-4284 (ISSN-L)
- OpenAlex
- W2977377261
- Cited by
- 37
- References
- 9
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. https://app.cochat.ai/papers/10.1200/po.19.00141
- The paper
- Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., Sherrill, G., Fanta, P., Grothey, A., Hendifar, A., Henry, D., Mahadevan, D., Nezami, M. A., Tan, B., Wainberg, Z. A., . . . Morris, V. (2019). Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precision Oncology. https://doi.org/10.1200/po.19.00141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.